Researchers say they've made a breakthrough in the study of psychedelics to treat disorders including major depression.
Source: Monash University press release
A cross-disciplinary team at Monash University in Australia used computational modeling to demonstrate that rats given psilocybin display long-lasting, increased optimistic behavior to perform reward-based tasks.
The findings, published in Translational Psychiatry, suggest psilocybin may be helpful for addressing the core symptoms of major depression and other conditions characterized by reduced engagement and withdrawal.
Monash PhD candidate Elizabeth (Beth) Fisher led the study, working with Professor Jakob Hohwy from the Monash Centre for Consciousness and Contemplative Studies (M3CS) and Dr.Claire Foldi from the Monash Biomedicine Discovery Institute.
The results are a promising step toward explaining the mechanisms of how psychedelics may work to change the brain and increase engagement after treatment, Hohwy said.
“Our team found that rats given psilocybin were more motivated to explore their environment and perform reward-based tasks,” he said. “These exciting results show the mechanisms of how psilocybin may work to increase optimism in an animal model, which we hope may translate to humans as well.”
Beth Fisher said the study should motivate confirmation of these effects in human studies.
“Insights into the mechanisms of psilocybin allow us to unpack who may benefit from psychedelic therapies as well as who these treatments may not be beneficial for,” she said. “With many people around the world affected by depression, our ultimate goal is to help build understanding of how psilocybin might be used to treat core symptoms people experience, such as diminished optimism, apathy and withdrawal from the world around them.”